Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients
Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients
复制标题
DOI：
10.1371/journal.pone.0212527
复制
发表时间：
2019-03-11
期刊：
影响因子：
3.7
通讯作者：
Jonsdottir, Kristin
中科院分区：
文献类型：
--
作者：
Egeland, Nina Gran;Austdal, Marie;Jonsdottir, Kristin
豆蔻酰化富含丙氨酸的C激酶底物样蛋白1（MARCKSL 1）的蛋白表达已被确定为淋巴结阴性（LN-）乳腺癌患者的预后因素。我们的目的是验证MARCKSL 1蛋白表达作为一个新的LN-乳腺癌患者队列的无远处转移生存期（DMFS）的预后标志物。应用免疫组化方法检测151例可手术的T1，2N 0 M0 LN-乳腺癌患者MARCKSL 1的表达。中位随访时间为152个月，范围为11-189个月。采用单因素（Kaplan-Meier）和多因素（考克斯模型）生存分析将结果与经典的预测因子（年龄、肿瘤直径、分级、雌激素受体和增殖）进行比较。13例患者（9%）发生远处转移。通过对所有特征的单因素和多因素分析，MARCKSL 1未显示出对DMFS的显著预后价值（p = 0.498）。在评估的经典预测因子中，只有肿瘤直径显示出预后价值（风险比9.3，95%置信区间2.8-31.0，p < 0.001）。MARCK SL 1表达在该队列中不能被证实为预后因素。可能的原因包括发现和验证队列之间诊断和治疗指南的变化。需要进一步的研究来揭示这种蛋白在乳腺癌中的潜在生物学作用。
Protein expression of Myristoylated alanine-rich C kinase substrate like-1 (MARCKSL1) has been identified as a prognostic factor in lymph-node negative (LN-) breast cancer patients. We aim to validate MARCKSL1 protein expression as a prognostic marker for distant metastasis-free survival (DMFS) in a new cohort of LN- breast cancer patients. MARCKSL1 expression was evaluated in 151 operable T1,2N0M0 LN- breast cancer patients by immunohistochemistry. Median follow-up time was 152 months, range 11-189 months. Results were compared with classical prognosticators (age, tumor diameter, grade, estrogen receptor, and proliferation) using single (Kaplan-Meier) and multivariate (Cox model) survival analysis. Thirteen patients (9%) developed distant metastases. With both single and multiple analysis of all features, MARCKSL1 did not show a significant prognostic value for DMFS (p = 0.498). Of the assessed classical prognosticators, only tumor diameter showed prognostic value (hazard ratio 9.3, 95% confidence interval 2.8-31.0, p < 0.001). MARCK SL1 expression could not be confirmed as a prognostic factor in this cohort. Possible reasons include changes in diagnostic and treatment guidelines between the discovery and validation cohorts. Further studies are needed to reveal the potential biological role of this protein in breast cancer.